Acemetacine: Pharmacological and clinical features;Acemetacina: Características farmacológicas y clínicas

Revista Mexicana de Anestesiologia

Volumn 27, Issue 1, 2004, Pages 33-56

  Guevara López, Uriah ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Immunology and Rheumatology Department   (Mexico)

Author keywords

Acemetacine; Analgesia; Anti inflammatory; COX2; NSAIDs

Indexed keywords

ACEMETACIN; ACETYLSALICYLIC ACID; AZAPROPAZONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOLEACETIC ACID; INDOMETACIN; INDOPROFEN; METHYL GROUP; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; SULINDAC; TOLMETIN;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APPETITE DISORDER; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; EDEMA; ENZYME INHIBITION; EPIGASTRIC PAIN; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INFLAMMATION; INSOMNIA; MOLECULAR WEIGHT; NONHUMAN; PAIN; PHYSICAL CHEMISTRY; REVIEW; RHEUMATIC DISEASE; SOMNOLENCE; STOMACH DISEASE; STRUCTURE ANALYSIS; TINNITUS; VERTIGO; VISUAL DISORDER;

EID: 19244380989     PISSN: 01851012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Donate MG, Van Den Eeckout E, Van Den Bossche W, Sandra P. Capillary zone electrophoresis and micellar electrokinetic chromatography of some non-steroidal anti-inflammatory drugs (NSA1Ds). Journal of Pharmaceutical and Biomedical Analysis 1993;3:197-201.
2. Mathies H, Wolff E. Study of the dose-reducing effect of acemetacin on prednisolon. Arzneimittelforschung 1980;30(8a):1438-1440.
3. Boltze KH, Brendler O, Jacobi H, Opitz W, Raddatz S, Seidel PR, Vollbrecht D. Chemical structure and anti-inflammatory activity in the series of substituted indole-3-acetic acids. Arzneimittelforschung 1980; 30(8a):1314-1325.
4. Honba K, Yamada T, Yoneda M, Ohkawa Y, Nagai H. Physicochemical properties and stabilities of acemetacin (k-708). Iyakuhin Kenkyu 1982;13(1):323-333.
5. Anonymous. Efficacy and tolerance as a demand-not as a contradiction: rantudil, rantudil forte, antirheumatic agent, antiphlogistic agent. Wiss Zentralbuero DFA Tropon-PMI-Pharm-and Medical-Information-Verlags-GMBH. 1984.
6. Jacobi H, Breier P, Dell HD. Anti-inflammatory action of acemetacin. Arzneimittelforschung 1980;30(8a):1326-1347.
7. Jacobi H, Dell HD. On the pharmacodynamics of acemetacina. Arzneimittelforschung 1980;30(8a):1348-1362.
8. Dell HD, Doersing M, Fiedler J, Fischer W, Jacobi H. Analytical methods and in vitro studies with acemetacin. Arzneimittelforschung 1980; 30(8a):1362-1370.
9. Dell HD, Doersing M, Fischer W, Jacobi H, Kamp R, Koehler G, Schoellnhammer G. Metabolism and pharmacokinetics of acemetacin in man. Arzneimittelforschung 1980;30(8a):1391-1398.
10. Kabuto S, et al. Studies on metabolic fate of acemetacin (k-708) in rats; absorption distribution and excretion of glycolic ester moiety of acemetacin. Jpn Pharmacol Ther 1982;10(1):39-48.
11. Arita T, Miyazaki K, Kohri N, Saitoh H. The behavior in gastro-intestinal tract and biliary excretion of acemetacina. J Pharm Soc Jpn 1982;102(5):477-483.
12. Jacobi H, Dell HD. Toxicology of acemetacina. Arzneimittelforschung 1980;30(8a):1398-1417.
13. Dell HD, Doersing M, Fischer W, et al. Biochemical studies on acemetacin; Experimental tests in animals. Arzneimittelforschung 1980;30(8a):1371-1383.
14. Jones RW, Collins AJ, Notariannil J, Sedman E. The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol 1991;31(5):543-545.
15. Kageyama T, Sugahara Y. Blood plasma concentration and urinary excretion of acemetacin after repeated administration to healthy subjects. Jpn Pharm Ther 1981;9(9):107-120 (3593-3606).
16. Simkin PA, Pizzorno JE. Synovial permeability in rheumatoid arthritis. Arthritis Rheum 1979;22(7):689-695.
17. Koehler G, Tressel W, Dell HD, Pelster B. Pharmacokinetics of acemetacin in synovial fluid, synovial membrane, muscle, and bone of patients with several forms of arthritis. Topics in arthritis and rheumatism, Ed. Pelster B., Raven press, New York: 1994:5-8.
18. Dell HD, Beckermann B, Doersing M, Fischer W, et al. Retard effect of acemetacin from a commercial preparation-kinetics in humans after single and multiple application. Arzneimittelforschung 1986;36(4):747-752.
19. Cashman JN. The mechanisms of action of NSAIDS in analgesia. Drugs 1996;52(suppl 5):13-23.
20. Weillin Xie, Robertson D, Simmons DL. Mitogen-inducible prostaglandin G/ H synthase: A new target for non-steroidal anti-inflammatory drugs. Drug Development Research 1992;25:249-265.
21. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and COX 2 inhibitors. Inflamm Res 1995;44(6):253-257.
22. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibition of isoforms of cyclooxygenase (cox-1, cox-2) in chronic inflammation. Inflamm Res 1998;47(2):79-85.
23. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347(1):87-94.
24. Tavares IA, Bennett A. Acemetacin and indometacin: differential inhibition of constitutive and inducible cyclo-oxygenases in human gastric mucosa and leukocytes. Int J Tissue React 1993;15(2):49-53.
25. Pelster B. Inhibition of PGE 2 synthesis in vivo by acemetacin and indomethacin. Topics Arthritis Rheum 1995;2:7-8.
26. Tavares IA, Bennett A. Acemetacin inhibits cyclooxygenase in human gastric mucosa less than in leukocytes. Topics in arthritis and rheumatism, Ed. Pelster B, Raven Press, New York. 1994:1-4.
27. va Edición 1998:398-409.
28. Hascelik G, Ercis S, Hascelik Z. Acemetacin as an inhibitor of neutrophil chemotaxis among the NSAID family. Top Arthritis Rheum 1995;2:5-6.
29. Felzenzwalb I, Asad NR, Alcantara-Gomes R. Antioxidant capacity of cyclo-oxygenase and lipoxygenase inhibitors. Braz J Med Biol Res 1980;20(6):873-875.
30. Tanaka M, Kakishita T, Kato Y, et al. Subacute toxicity study of acemetacin (k-708) in dogs. Pharmacometrics 1981;22(5):685-708.
31. Tuschl P, Wottawa A, Heiter A, Tausch G. Influence of acemetacin on DNA repair and DNA synthesis in vitro and in vivo. Arzneimittelforschung 1980;30(8a):1418-1421.
32. Ota T, Tsuruta T, Yoshimura M, Kobayashi F. Placental passage and ductus-constricting effect of acemetacin in rats. J Toxicol Sci 1984;9(3):296.
33. Okubo M, Tsuruta T, Kato, et al. Acute toxicity study of acemetacin and its metabolites. Pharmacometrics 1981;22(5):657-664.
34. Nakamura M, Yoshinaka Y, Suzuki H, Wada Y. Irritative effects of acemetacin and indomethacin on the gastro-intestinal tracts of rats. Folia Pharmacol Jpn 1981;78(5):511-519.
35. Uthgenannt H, Havemann R, Mohing W, et al. The influence of acemetacin and indomethacin on gastrointestinal blood loss in normal volunteers and rheumatic patients. Arq Bras Med 1986;60(6):527-530.
36. Mueller P, Dammann GH, Simon B. Gastroduodenal tolerability of indomethacin and acemetacin. An endoscopic study in healthy volunteers. Arzneimittelforschung 1986;36(2):269-270.
37. Bernhard I, Rechziegler H, Zuendorf P, Bernuth K Von. Inhibition of renal cyclooxygenase activity by NSAIDS. 6th Int Conf Prostaglandins Rel Comp, Florence, Italy, 1986:43.
38. Motohashi N. Experimental and clinical studies on the effect of nonsteroidal anti-inflammatory agents on glomerular proteinuria. Tokyo Jikeikai Med J 1986;101(4):679-698.
39. Duerrigl TH. Multimorbidity in rheumatic patients and subsequent drug interactions-especially in older people. Second International Symposium on Etofenamate, Athen 17-19. 1983:108-111.
40. Thebud-Lassak R, Rechziegler H. Non-steroidal anti-inflammatory agents in the elderly. ZFA (Stuttg) 1989;65(25):615-620.
41. Zoeller B, Bernuth K Von, Rechziegler H. Effect of acemetacin on digoxin plasma concentration. XVIITH ILAR Congress Rheumatology. Rio de Janeiro, Brasil. 17-23. 1989:275.
42. Dullenkopf B, Thebud-Lassak R, Rechziegler H. Interaction studies with acemetacin. Clin Exp Rheumatol 1990;8(suppl 4):82.
43. Moura D. Interactions of nonsteroidal antiphlogistics with anti-hypertensive drugs. Int Symp Newer Aspects Rational Antirheumatic Ther, Funchal, Pt, 1984.
44. Haupt E, Hoppe Fk, Rechziegler H, Zuendorf P. Possible interaction between non-steroidal anti-inflammatory drugs and oral antidiabetic agents: acemethacin and glibenclamide. Z Rheumatol 1987;46:170-173.
45. Ridell J, Silke B, Jeffers L, Wickens CJ, Sedman E, Notarianni LJ. Effect of acemetacin on the anticoagulant action of warfarin in healthy volunteers. Focus on Acemetacin, Congress of Rheumatology, Barcelona, 1993:23-27.
46. Shiokawa Y, Nobunagawa T, Ofuji M, Ohara A, et al. Clinical study of acemetacin (k-708) in rheumatoid arthritis. Jpn J Pharm Ther 1981;9(4):359-375.
47. Spechtmeyer H. Long-term trials with acemetacina. Int Symp Newer Aspects Rational Antirheumatic Ther, Funchal, Pt, 1984.
48. Stroehmann I. Acemetacin therapy in inflammatory rheumatic diseases: results of a double-blind study. Therapiewoche 1986;36(43):4450-4455.
49. Badia-Flores J, Munoz Barradas F. The treatment of rheumatoid arthritis with acemetacin and indomethacin. Arzneimittelforschung 1980;30(8a):1433-1437.
50. Heiter A, Tausch G, Eberl R. Comparison of acemetacin with indomethacin in a controlled double blind study on patients suffering from rheumatoid arthritis. Arzneimittelforschung 1980;30(8a):1427-1433.
51. Heiter A, Tausch G, Eberl R. Results of a long-term study with acemetacin in the therapy of patients suffering from rheumatoid arthritis. Arzneimittelforschung 1980;30(8a):1460-1463.
52. Iwata H, Nagaya I, Matsui N, Ohkaya M, Miyashita N. Investigation on long-term administration of acemetacin in rheumatoid arthritis. XIth Eur Congress Rheumatology, Athens, Greece, 1987:F-147.
53. Miehlke K, Pfannnenstiel P. Acemetacin and indomethacin in patients with rheumatoid arthritis during control by joint-scintigraphy. Therapiewoche 1987;37(28):2727-2733.
54. Schroeder M, Chow W, Pfannenstiel P. Acemetacin and indomethacin in patients with chronic polyarthritis: a double-blind study using joint scintigraphic controls. XVth International Congress Rheumatology, Paris, 21-27.06. 1981:1-4.
55. Siegmeth W, Broll H, Schragl F. Acemetacin in treatment of painful arthrosis. Wien Med Wochenschr 1984;134(22):505-508.
56. Kuecuekoglu S, Turan B, Ceylan S, Dogan M. Comparison of etodolac and acemetacin in the treatment of knee osteoarthritis. Rheumatol Europe 1995;24(suppl 3):329.
57. Kuecuekoglu S, Turan B, Ceylan S, Dogan M. Comparison of etodolac and acemetacin in the treatment of knee osteoarthritis. Top Arthritis rheuma 1995;2:17-22.
58. Wietfeld K, Bernard I, Ruebsamen B, Rechziegler H. Therapy with acemetacin and diclofenac in patients with degenerative joint disease. Med Welt 1986;37(34-35):1073-1076.
59. Bird HA, Grant M, Hopkins R, Sedman E, Webb FWS, Wojtulewski J. Acemetacin and naproxen in the treatment of elderly patients suffering from Osteoarthritis. Br J Clin Res 1992;3:77-84.
60. Pelster B. Acemetacin in osteoarthritis. Focus on Acemetacin, Congress of Rheumatology, Barcelona, 1993:17-21.
61. Hopkins R, Bird HA, Grant M, Sedman E, Webb FWS, Wojtulewski J. Acemetacin and naproxen in the treatment of elderly patients suffering from osteoarthritis. Focus on Acemetacin, Congress of Rheumatology, Barcelona, 1993:5-9.
62. Kronhagel R. Clinical results of a double blind study with the new antirheumatic agent acemetacin. Arzneimittelforschung 1980;30(8a):1445-1448.
63. Lonauer G, Wirth W. Controlled double blind study on the efficacy and tolerability of acemetacin and indomethacin in the therapy of psoriatic arthritis. Arzneimittelforschung 1980;30(8a):1440-1444.
64. Schattenkirchner M, Kellerer G, Krueger K. Single-blind, crossover comparison study with acemetacin and diclofenac. Therapiewoche 1986;36(51):5276-5283.
65. Reiter W, Pilger A. Ankylosing spondylitis: a comparison of acemetacin and piroxicam. Therapiewoche 1984;34(52):7209-7215.
66. Scheines EJ P, Prado-Isla LH DE. Double-blind controlled trial of acemetacin, nimesulide and piroxicam in soft tissue rheumatism. Prensa Med Argent 1996;83(6):584-587.
67. Pelster B. Acemetacin in the treatment of glomerulonephritis. Ilar Congress of Rheumatology, Singapore, 1997:1.
68. Tsuchida H, Yamamoto S. Clinical study of acemetacin on patients with chronic glomerulonephritis and nephrotic syndrome. Jpn J Clin Exp Med 1984;61(11):299-308.
69. Mitani S, Nakano S, Chien H. Experience with long-term application of acemetacin (k-708). Jpn J Pharmacol Ther 1981;9(3): 1151-1163.
70. Bach GL. Clinical results of a double-blind study of the non-steroidal anti-rheumatic agents acemetacin and indomethacin. Rheumamedizin 1982;4(2):78-83.
71. Meyer-Rohn J. Indication of acemetacin in dermatological diseases. Arzneimittelforschung 1980;30(8a):1458-1459.
72. Amako T, Ogawa N, Iwabuchi T. Clinical evaluation of acemetacin in periarthritis scapulohumeralis double blind comparative study with indomethacin. Jpn J Pharmacol Ther 1981;9(5): 2157(439).
73. Shimazu A, Hirohashi K. Clinical study of k-708 (acemetacin) on degenerative gonarthrosis knee. Jpn J Pharm Ther 1981;9(11): 323-343.
74. Doerfler H. Therapy of acute gout attacks with acemetacin. Therapiewoche 1985;35(11):1161-1166.
75. Erggelet C, Ogon M, Schaffner J. Prophylaxis with acemetacin to prevent heterotopic ossifications after primary hip joint arthroplasty. Topics in Arthritis and Rheumatism, ed. Pelster B., Raven Press, New York. 1994:17-21.
76. Nishijima S, Sugiyama T, Nakagawa M, Odake T, Takaishi K. Two cases of eosinophilic pustular folliculitis treated by acemetacin. J Dermatol 1994;21(10):779-782.
77. Szabados T. Double-blind trial of acemetacin and phenylbutazone for pain and inflammation after episiotomy. Med Welt 1986;37(21): 703-706.
78. Schmetzer. Prophylaxis and therapy of postoperative edema with acemetacin in oral, jaw and facial surgery. Dtsch Z Mund Kiefer Gesichtschir 1987;11:454-459.
79. Kitamoto O, Kobayashi H, Kaji M, Kashiwagi S, et al. A clinical study on the effect of k-708 (acemetacin)-a double blind comparative study with ibuprofen in upper respiratory tract inflammation with fever. J Jpn Assoc Infect Dis 1981;55(9): 614-629.
80. Neugirg R, Penners R. Clinical trials with acemetacin on children and adolescents. Arzneimittelforschung 1980;30(8a): 1451-1454.
81. Herrera-Gómez L, De la Selva S y cols. Estudio clínico abierto, para evaluar la eficacia y seguridad de la acemetacina en los procesos inflamatorios de origen odontológico. Revista Para la Salud 2001;6(51):44-56.
82. Bori-Segura G, Torres-GR A, Herrera-Gómez L, Olguín-Uribe J. Etapam. Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients, result of the ATA-PAM study. Proc West Soc 2002;45:104-107.